Your search returned 72 results.
Legend: - AAccuray
- CCyberKnife
- TTomoTherapy
-
The CyberKnife® System successfully reproduced an HDR-like dose distribution, delivering treatment in a minimally invasive fashion.
-
How Renown Institute for Cancer is using the TomoTherapy® Hi•Art® treatment system to maintain leadership in a competitive market.
-
Using the TomoTherapy® Hi·Art® system’s precise dose guidance capabilities, the oncologist delivered intense radiation directly to the tumor during a week and a half of treatment. The patient experienced no side effects during this time and continued to work as a nurse. Three years later, she remains disease free.
-
We modeled the use of an imaged guided simultaneous infi eld boost (SIB) to individual metastases during a course of whole brain radiotherapy using helical TomoTherapy.
-
-
After years of working with equipment that had fragmented IG-IMRT capabilities from multiple vendors, the trust team wanted a truly integrated image-guided and intensity-modulated package.
Pages
-
This study is an international multicenter randomized study of organ confined low and intermediate risk prostate cancer and is composed of two parallel randomization schemes based on applicability of surgery as a treatment for the patient. Patients for whom surgery is a consideration are randomized to either laparoscopic or da Vinci prostatectomy or CyberKnife prostate SBRT(also known as CyberKnife radiosurgery). Patients for whom surgery is not a consideration are randomized to either conventionally fractionated radiation therapy or CyberKnife prostate SBRT. Efficacy, toxicity and quality of life outcomes will be compared across the pairs in each randomization.
-
This prospective, multicenter study is intended to establish the efficacy and toxicity of treating unresectable colorectal liver metastases with accurately administered radiation using the CyberKnife stereotactic radiosurgery system.
-
The purpose of this study is to assess the short and long-term outcomes after CyberKnife stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable.
-
Although more patients studied over an even longer follow-up period are needed to determine the long-term efficacy of spinal radiosurgery for benign extra-axial neoplasms, short-term clinical benefits were observed in this prospective analysis. The present study demonstrates that CyberKnife radiosurgical ablation of such tumors is technically feasible and associated with low morbidity.
-
Data indicate that CyberKnife treatment plans with excellent homogeneity, conformity and percent target coverage can be obtained for complex skull base tumors.
-
Helical tomotherapy (HT) can potentially be used for lung cancer treatment including stereotactic radiosurgery because of its advanced image guidance and its ability to deliver highly conformal dose distributions.
-
The Xsight spine tracking system is practically important because it is accurate and eliminates the use of implanted fiducials. Experience has shown this technology to be robust under a wide range of clinical circumstances.
-
Image-guided robotic stereotactic radiosurgery of lung tumors with CyberKnife(R) achieves excellent rates of local disease control with limited toxicity to surrounding tissues and, in many cases, might be curative for patients for whom surgery is not an option.
-
Thirteen of the 18 tumors (72%) showed a volume decrease. The average volume change was a decrease of 16 +/- 58% (median: 20%) with a follow-up of 180 +/- 121 days (median: 172 days). Toxicity occurred in only one patient, with symptoms improving on steroids.
Pages
This section provides CyberKnife and TomoTherapy case studies, created by Accuray in collaboration with our centers, showcasing positive outcomes. Individual treatment results may vary. Please consult a physician to discuss individual cases, including eligibility for treatment with Accuray devices.
This section also provides a selected list of publications supporting the use and efficacy of the CyberKnife and TomoTherapy Systems and is not inclusive of all available publications.
For access to a more comprehensive listing of publications related to CyberKnife and TomoTherapy Systems, visit www.pubmed.com.
© 2007 - 2013 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi•Art, and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries. Privacy Policy
